Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...
Efficient production of Adeno-Associated Virus (AAV) vectors at scale for in vivo gene therapies remains a key bottleneck for broad patient access and sustainable manufacturing costs. -- Virica and ...
VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree™ AAV, a ...
New expedited service line designed for biotechs with timeline constraints, launched in response to client demandCan accelerate timeline to GMP ...
Researchers from MIT have developed a bioreactor simulator to predict adeno-associated virus (AAV) yields for insect cell/baculovirus manufacturing. Francesco Destro, PhD, a postdoctoral associate ...
A team of Portuguese scientists has reduced the size of helper plasmids for recombinant adeno-associated viral (rAAV) production. The team, from Instituto de Biologia Experimental e Tecnológica (iBET) ...
With years of experience in the pharmaceutical and life science sectors, CD Bioparticles is proud to announce the launch of its new line of Alkali-Tolerant AAV Affinity Agarose Resins. Specifically ...
Safe and effective gene therapy strategies depend on robust and reliable adeno-associated virus (AAV) mediated therapeutic gene delivery. However, scaling up AAV manufacturing to obtain sufficient ...
The viral vector specialist SIRION Biotech has announced the signing of a preferred partnership agreement with Heidelberg University Hospital ...
VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree AAV, a high-stability AAV vector designed to address ITR instability, a common challenge in ge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results